Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rising PSAs after primary therapy: active or passive intervention.

S F Slovin1, H I Scher

  • 1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

Seminars in Urologic Oncology
|August 26, 1999
PubMed
Summary

For men with biochemically recurrent prostate cancer after initial treatment, new therapies offer antitumor effects with minimal side effects. This review explores alternative and immunological treatments for managing rising PSA levels without compromising survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

European journal of cancer (Oxford, England : 1990)·2021
Same author

Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Periprostatic adipose inflammation is associated with high-grade prostate cancer.

Prostate cancer and prostatic diseases·2017
Same author

Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Collaborating to Compete: Blood Profiling Atlas in Cancer (BloodPAC) Consortium.

Clinical pharmacology and therapeutics·2017

Area of Science:

  • Oncology
  • Immunology
  • Urology

Background:

  • Biochemically recurrent prostate cancer after primary treatment (prostatectomy, radiation) presents a significant therapeutic challenge.
  • Standard treatment options are lacking, with androgen ablation often offered despite potential quality-of-life impacts.
  • Patients may delay hormonal therapy, seeking alternative approaches to manage rising prostate-specific antigen (PSA) levels.

Purpose of the Study:

  • To review novel therapeutic approaches for patients with biochemically recurrent prostate cancer.
  • To identify treatments with potential antitumor effects and minimal toxicity for this patient subgroup.
  • To explore the benefits of immunological and alternative therapies in managing recurrent prostate cancer.

Main Methods:

Related Experiment Videos

  • Literature review of recent studies and clinical trials.
  • Analysis of emerging treatments focusing on immunological and alternative modalities.
  • Evaluation of treatment efficacy, toxicity profiles, and impact on PSA levels.

    • Main Results:

    • Several new approaches demonstrate promising antitumor activity.
    • These alternative and immunological therapies show potential for minimal side effects compared to traditional treatments.
    • Management of rising PSA is achievable with these novel strategies.

    Conclusions:

    • Novel immunological and alternative therapies represent a viable option for men with biochemically recurrent prostate cancer.
    • These approaches may offer effective disease control with improved quality of life.
    • Further research is warranted to establish standard protocols for these emerging treatments.